OVERVIEW
This complimentary CME activity, entitled "Recurrent Glioblastoma: Current Obstacles & Future Directions in Care," consists of a program overview, a presentation, a learning assessment, and an evaluation form.

MEDIA: Virtual Lecture or Podcast
INTERNET RELEASE DATE: December 31, 2010
(Continuing education credit is no longer available for this activity.)

Estimated time to complete this activity: 1 hour

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncologists, neuro-oncologists, neuro-radiologists, neurosurgeons, and radiation oncologists who are involved in the care of patients with glioblastoma.

STATEMENT OF NEED
The management of recurrent glioblastoma multiforme (GBM) is associated with numerous diagnostic and treatment challenges. Defining recurrent GBM and understanding its epidemiology is difficult due to variations in definition and criteria used by institutions and in clinical studies.1 To accurately determine a patient’s prognosis, various diagnostic techniques are being investigated to distinguish GBM from pseudoprogression and radiation necrosis.2 Once recurrence has been confirmed, treatment options include re-operation, radiation, and commonly, chemotherapy; however, available therapies have limitations.3 For this reason, researchers continue to investigate innovative diagnostic techniques and targeted therapies, many of which may hold promise for improved patient outcomes. Healthcare professionals who treat patients with recurrent GBM must be aware of the latest research findings to choose the most effect.ive diagnostic and treatment strategies for their patients.

1 Reithmeier T, et al. BMC Cancer. 2010;10:30.
2 Yang I, et al. Nat Rev Clin Oncol. 2009;6(11):648-657.
3 Desjardins A, et al. Biologics. 2009;3:15-25.

EDUCATIONAL OBJECTIVES
After participating in this activity, the participant should better be able to:

• Discuss the definition and epidemiology of recurrent glioblastoma multiforme (GBM)
• Utilize best practice imaging modalities for recurrent GBM, including those that distinguish tumor recurrence from treatment-related effects
• Practice evidence-based strategies that include the use of current and novel treatment options for newly diagnosed and recurrent GBM
• Assess clinical data on emerging GBM therapies

METHOD OF PARTICIPATION
There are no fees for participating in and receiving CME credit for this activity. During the period December 31, 2010, through December 31, 2011, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the learning assessment by recording the best answer to each question in the "Learning Assessment Answers" box on the evaluation form; 4) complete the evaluation form; and 5) mail or fax the evaluation form with the learning assessment answers to Albert Einstein College of Medicine.

PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Albert Einstein College of Medicine and Robert Michael Educational Institute LLC (RMEI). Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
Albert Einstein College of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

FACULTY
Patrick Y. Wen, MD
Professor of Neurology
Director, Allergy and Immunology Fellowship Program
Harvard Medical School
Director
Center For Neuro-Oncology
Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center
Boston, Massachusetts

DISCLOSURE OF CONFLICTS OF INTEREST
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical, product, or device company. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

Albert Einstein College of Medicine, Center for Continuing Medical Education, and RMEI staff have no conflicts of interest with commercial interests related directly or indirectly to this educational activity.

The faculty reported the following financial relationship or relationships to products or devices that they or their spouse/life partner have with commercial interest related to the content of this CME activity:

Patrick Y. Wen, MD, has affiliations with Boehringer Ingelheim; Amgen; Astra Zeneca; Esai; Exelixis; Genentech; Merck; Novartis (Research Support) and Ark Therapeutics; Agios; Genzyme; Novartis; Imclone/Lilly (Advisory Board).

Dr. Wen will be discussing drugs that are unlabeled or used for investigational purposes.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Albert Einstein College of Medicine, Center for Continuing Medical Education, RMEI, and EMD Serono do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Albert Einstein College of Medicine, Center for Continuing Medical Education, RMEI, and EMD Serono. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.

ASSISTANCE
For CME assistance, contact cme@montefiore.org.

SYSTEM REQUIREMENTS
Hardware/Software requirements include:
• 2000, XP, Vista, Windows 7   
  - Internet Explorer 6.0+
• Macintosh 9.2, OS X 10.1+
  - Safari 4
• Additional Requirements
  - Macromedia Flash Player 7
  - Internal/external speakers
  - Broadband connection (DSL/cable) recommended

FOR MORE INFORMATION:

Einstein Privacy Policy        RMEI Privacy Statement